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To mimic the extreme germline and somatic genetic heterogeneity in human samples, we bred Mus musculus mice (FVB/N) with a wild-derived strain, Mus spretus (SPRET/EiJ), to create a heterogeneous backcross population (hereafter referred to as FVBBX) (Fig. 1a) and carried out chemical carcinogenesis with dimethylbenzanthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). Squamous carcinomas (SCCs) in this model almost always carry mutations in Hras 6 , which is also a driver of squamous carcinogenesis in human head and neck 7 and skin 8 . To compare routes to carcinoma development that are driven by Hras or Kras 5, 9 , which are mutated in many human cancers 10 , we also bred Hras −/− FVBBX mice that develop aggressive tumors carrying Kras mutations after DMBA-TPA treatment 5 . To further mimic human clinical practice, we surgically removed primary carcinomas, allowing continued survival and subsequent harvesting of distant metastases (Fig. 1a) 5 . We selected 103 tumor samples from 15 animals (9 wild-type and 6 Hras −/− mice)-for which matched normal tissue, benign papillomas, carcinomas and metastases were available-and carried out whole exome-sequencing and gene expression microarrays (Supplementary Table 1 ).
RESULTS

Mutation spectrum of early and late mutations
The predominant mutation found in tumors from wild-type FVBBX mice was the classical A-to-T transversion in the Hras gene 6, 11 , leading to Q61L mutations (in 58 tumors from 9 mice). By using a nested-PCR approach 12 , this mutation can be detected as early as 1 week after DMBA treatment, but the skin remains morphologically normal for periods of up to 1 year in the absence of further treatment with TPA 13 . Tumors from Hras −/− mice had Kras mutations at a range of 'hot spot' sites-G12D, G13R, Q61L and Q61H (in 26 tumors from 6 mice) (Supplementary Table 1 ). Both Hras and Kras mutations showed a strong preference for the FVB allele in mice heterozygous at these loci (84% and 100% specificity, respectively; P < 0.001, Supplementary Fig. 1 ), consistent with previous work indicating allelic preference for Ras mutations in mouse models 14, 15 . A single mouse carried no Hras or Kras mutations, but it had several tumors with a mutation in Pik3ca, which encodes phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit alpha, at the most common hot spot (H1047L) found in human cancers 16 .
Tumors carried an average of 237 SNVs (5.2 mutations/Mb), which is similar to the mutational burden of human adenocarcinomas and SCCs of the lung 17 . Papillomas harbored fewer mutations than did age-matched primary carcinomas (172 versus 284 mutations on average, respectively; P = 0.01; Supplementary Table 2), but whether this is due to differences in DNA repair, proliferation or increased genomic instability during progression is presently unclear. The genome-wide mutation spectrum across all 103 tumors showed an enrichment in DMBA signature transversion mutations (i.e., A-to-T mutations; hereafter referred to as A>T; 45% of all mutations), predominantly at 2 of the 96 possible trinucleotide contexts (Fig. 1b) 18 .
Mutations in metastases that were shared with a matched primary tumor showed an enrichment of A>T DMBA signature mutations (63% of all mutations). Subsequent non-shared mutations were predominantly G-to-T mutations (hereafter referred to as G>T mutations; 50%, as compared to 14% of shared mutations; Fig. 1c) . Subclonal mutations Trinucleotide context   Trinucleotide context  Early mutations  Late mutations   Trinucleotide context   Trinucleotide context   T>A  T>C  T>G  C>A  C>G  C>T  T>A  T>C  T>G   C>A  C>G  C>T  T>A  T>C  T>G  C>A  C>G  C>T  T>A  T>C ACG>A  ACT>A  CCA>A  CCC>A  CCG>A  CCT>A  GCA>A  GCC>A  GCG>A  GCT>A  TCA>A  TCC>A  TCG>A  TCT>A  ACA>G  ACC>G  ACG>G  ACT>G  CCA>G  CCC>G  CCG>G  CCT>G  GCA>G  GCC>G  GCG>G  GCT>G  TCA>G  TCC>G  TCG>G  TCT>G  ACA>T  ACC>T  ACG>T  ACT>T  CCA>T  CCC>T  CCG>T  CCT>T  GCA>T  GCC>T  GCG>T  GCT>T  TCA>T  TCC>T  TCG>T  TCT>T  ATA>A  ATC>A  ATG>A  ATT>A  CTA>A  CTC>A  CTG>A  CTT>A  GTA>A  GTC>A  GTG>A  GTT>A  TTA>A  TTC>A  TTG>A  TTT>A  ATA>C  ATC>C  ATG>C  ATT>C  CTA>C  CTC>C  CTG>C  CTT>C  GTA>C  GTC>C  GTG>C  GTT>C  TTA>C  TTC>C  TTG>C  TTT>C  ATA>G  ATC>G  ATG>G  ATT>G  CTA>G  CTC>G  CTG>G  CTT>G  GTA>G  GTC>G  GTG>G  GTT>G  TTA>G  TTC>G  TTG>G  TTT>G C>G C>T Figure 1 Chemically induced tumors carry a mutation signature of the carcinogen DMBA. (a) Scheme for the generation of genetically unique backcrossed (FVBBX) mice and of metastases. FVB/N Hras −/− mice were crossed with SPRET/EiJ mice and the resulting offspring were crossed to inbred wild-type (WT), Hras +/− or Hras −/− FVB/N mice to generate a backcross population with all three Hras genotypes. Tumors were induced in FVBBX mice, carcinomas were resected upon reaching >1 cm in the longest diameter, and mice were allowed to progress to metastatic disease. (b) Frequencies of mutations observed in each of 96 possible trinucleotide mutation contexts for all of the mutations across all tumors. Trinucleotide contexts, arranged on the x axis, are grouped by the base pair change of the mutation. Peaks are observed at two specific contexts, CTG to CAG and GTG to GAG. The same pattern is also observed when only nonsynonymous mutations are considered (data not shown). (c) Frequencies of 'early mutations' (left graphs) or 'late mutations' (right graphs) in metastases, as classified by two strategies. Top, mutations were classified by whether they are shared with the ancestral primary tumor (early, upper left) or not shared (late, upper right). Bottom, mutations in tumors of all stages were classified on the basis of whether they were fully clonal (i.e., present in all tumor cells; early; lower left) or subclonal (i.e., present only in a fraction of tumor cells; late; lower right). Early mutations show an enrichment of A>T mutations (equivalent to T>A mutations on the opposite strand), and late mutations show a higher proportion of G>T mutations (equivalent to C>A mutations on the opposite strand). in tumors of all stages were also much more likely to be G>T than A>T substitutions (Fig. 1c) . The average mutant allele fraction of A>T mutations was significantly higher than that of G>T mutations (0.265 versus 0.190, P = 2.2 × 10 −16 ), consistent with A>T mutations being early and clonal, and G>T mutations occurring later and more frequently being subclonal. These data suggest that most G>T mutations are not directly induced by DMBA but arise during subsequent tumor growth owing to increased genomic instability or oxidative stress.
Evolutionary trees reveal patterns of metastatic dissemination
We constructed phylogenetic trees 19 demonstrating the evolutionary relationships among papillomas, carcinomas and metastases from each mouse ( Fig. 2 and Supplementary Fig. 2 ). In 7 of 8 cases in which multiple metastases originated from a single primary carcinoma, the number and identity of mutations shared with the primary carcinoma were almost identical between metastases, suggesting that dissemination had occurred synchronously and in parallel. However, both primary tumor and metastases continued to evolve, and each tumor accumulated many private mutations after divergence. Tumor cells can disseminate at an early stage, before the evolution of overt carcinomas 4 , but the relationship between these early circulating cells and the outgrowth of metastasis is still unclear. In the skin model, metastasis occurred at different points during tumor evolution, in some cases diverging after many mutations had accumulated, whereas in others diverging after relatively few mutations had accumulated. In mouse 1664 (Fig. 2a) , 46% of total SNVs and only 17% of G>T substitutions were shared between carcinoma A and its four metastases. In contrast, nearly 88% of SNVs and 66% of G>T substitutions were shared among carcinoma A and its four metastases in mouse 1383 (Fig. 2b) . Other mice had more intermediate distributions (Fig. 2c-f and Supplementary Fig. 2 ). We conclude that although dissemination may be able to occur at an early stage, additional factors determine whether these circulating cells can lead to seeding and growth of metastases. Moreover, the timing of dissemination seems to be unrelated to the total mutational burden of the primary tumor.
These data also provide information on possible routes of dissemination. If metastasis occurs first to a regional lymph node and subsequently to distant sites, as proposed in the 'linear evolution' model 4 , then the metastases should be more genetically related to each other than to the primary carcinoma. This is in fact seen in only one animal (mouse 1949, Fig. 2f) . In most cases, each metastasis was genetically distinct, supporting a model of independent, parallel spreading from the primary tumor. Furthermore, metastases to lymph nodes do not always depart the primary tumor first; in mouse 1407, the spleen metastasis departed first (Fig. 2c) .
In some cases, carcinomas developed that showed no signs of metastasis, even in the presence of other metastatic carcinomas in the same animals (such as in mouse 1664, 1383, 2104 and 1949, Fig. 2 ; and in mouse 1508, Supplementary Fig. 2 ). This suggests that some carcinomas are intrinsically metastatic, whereas others are restrained from forming metastases at distant sites, possibly through immune surveillance 20 , lack of appropriate 'niche' factors or other tumor-specific mechanisms 21 . Comparative analysis of mutations in metastasizing and non-metastasizing primary tumors did not reveal any obvious candidate metastasis driver mutations (see Online Methods). Gene expression analysis identified Pdlim7 (also known as LMP1 in humans, a known downstream target of transforming growth factor (TGF)-β1 signaling 22 ) as a more highly expressed gene in metastasizing tumors than in non-metastasizing primary tumors (P = 6.4 × 10 −6 ). Several other genes were suggestive of being differentially expressed but did not meet the threshold for significance, including Cd151 (P = 1.4 × 10 −4 ), a cell surface glycoprotein involved in cell adhesion, integrin trafficking and metastasis 23, 24 . Expression levels of Pdlim7 and Cd151 are correlated with each other in carcinomas from this data set (Spearman's rank correlation coefficient (ρ) = 0.77; P = 6.7 × 10 −6 ) as well as in an independent set of mouse carcinomas (ρ = 0.52; P = 2.2 × 10 −5 ) (ref. 25) and in the Cancer Genome Atlas (TCGA) profiles of human head and neck cancers (ρ = 0.67) (refs. 26,27) .
Mesenchymal-to-epithelial transition depends on the metastatic site
Metastases to all organs except the lung-including the lymph nodes, kidney, liver, spleen and thymus-nearly always matched the squamous or spindle morphology of the primary tumor (21 of 22 cases, 95%). Metastases to the lung were almost always squamous (7 of 9 cases, 78%; one of the seven cases had mixed SCC and spindle morphology), even when they arose from primary tumors with spindle morphology. This finding is consistent with previous observations of metastases to the lung with squamous morphology in an inbred FVB/N model 5 ; however, here we were able to sequence-match these metastases to their respective primary tumors (Supplementary Table 3 ) and demonstrate that squamous lung metastases could arise from a primary spindle tumor, even when all other metastases from that tumor were of spindle morphology ( Fig. 3 and Supplementary Table 3 ). These data suggest that the requirement for mesenchymal-toepithelial transition (MET) for the outgrowth of metastases at distant sites 28 , which predicts epithelial-like squamous metastases, may in fact depend on the specific organ site: MET may be favored in the lung, but not in the soft tissue sites in which spindle metastases were frequently found.
Mutations shared with human SCCs
This analysis identified a large number of recurrently mutated genes in addition to Hras and Kras, many of which are reported to be mutated in human SCCs of the head and neck, skin and lung 7, 8, 29 . (Fig. 4 and Supplementary Table 4 ). These included recurrent mutations in Trp53, Fat1 and genes in the Notch signaling pathway, including Notch1, Notch3 and Trp63 (Fig. 4) . Dysregulation of Notch signaling, which is involved in epithelial differentiation, has been implicated in a variety of human SCCs 7, 8, 29 . The three mutations we observed in Notch1 and Notch3 were all in the N-terminal epidermal growth factor (EGF)-like repeat domains responsible for Ca 2+ ligand binding, and were probably inactivating mutations, as expected for SCCs, rather than activating mutations as seen in human leukemias 7, 8 . Recurrent mutations were also seen in Ep300, Apc, Ncor1, Syne1, Syne2, Ros1 and Dnmt1, all of which are mutated in human tumors. Single mutations were also seen in Pik3ca and Casp8 (consistent with those seen in head and neck SCC (HNSCC)), in Bbs9, Dclk1 and Kmt2c (consistent with those seen in cutaneous SCCs), and in Keap1 (consistent with those seen in lung SCCs). Among these, stop-gains (mutations that create stop codons) were seen in Apc, Ncor1 and Dclk1.
Dependence of CNVs on initiation by Hras or Kras mutations
We used the whole-exome sequencing data to construct copy number profiles for all of the tumors. Copy number gains of chromosome 7 (on which Hras is located) were seen in tumors from wild-type mice but not Hras −/− mice, pointing to Hras as the driving force behind whole chromosome 7 gains. Undifferentiated spindle tumors did not have chromosome 7 gains, in line with our observation that spindle carcinomas have reduced Hras expression 5 . Copy number gains of chromosome 6, previously noted by karyotype analysis 30 , were seen in tumors from both wild-type and Hras −/− mice (Fig. 5a) To understand what might be driving the copy number gains of chromosome 1, we searched for genes on chromosome 1 that were expressed at significantly higher levels in squamous tumors that had chromosome 1 copy number gains as compared to those that did not (Fig. 5a) . Nuak2, which encodes an AMP protein kinase (AMPK)-related kinase, showed the greatest significant change in expression (1.7-fold increase, P = 5.3 × 10 −5 ), and changes in expression of Itpkb (which encodes inositol 1,4,5-trisphosphate-3-kinase B) and Cflar (which encodes caspase 8 and FADD-like apoptosis regulator) were also significant (P = 5.1 × 10 −6 for Itpkb; P = 1.1 × 10 −4 for Cflar; Supplementary Table 5 ). Nuak2 expression levels were strongly correlated with Hras expression levels in tumors from wildtype mice in this study (ρ = 0.63, P = 1.9 × 10 −9 ), as well as in an independently derived data set 25 (ρ = 0.58, P = 1.3 × 10 −6 ). Nuak2 has been implicated in human cancer development by copy number gains in human melanoma 31 , in breast and liver carcinomas 26, 27 and, to a lesser extent, in HNSCC and lung SCC 7, 8 , and is therefore a possible therapeutic target. However, other genes, including those shown in Supplementary Table 5 , may also have a role in promoting the development of Hras-driven squamous carcinomas.
Among the most frequent copy number changes in aggressive human cancers are deletions at the CDKN2A locus on chromosome 9p and amplification or copy number gains of MET 29, 32 , both of which we also observed in our cohort. Cdkn2a was deleted in 52 tumors (50%), including nearly all spindle tumors (27 of 29 tumors, 93%) (Fig. 5b,c) 5, 33 . Met showed copy number gains in 47 tumors (46%), as the result of both focal amplifications (6 tumors) and of whole gains of chromosome 6 (41 tumors). Both the occurrence and co-occurrence of these lesions increased dramatically with tumor stage: both events were rare in papillomas, but in SCCs, 63% of tumors had either a Cdkn2a loss or a Met gain, and 25% had both. In spindle tumors, nearly all tumors had a Cdkn2a loss or a Met gain, and 59% of tumors had both (Fig. 5c) .
Acquisition of SNVs precedes CNVs during progression
To verify the timing of SNV and CNV acquisition during tumor progression, we sequenced a set of 18 early, small (2-4 mm in diameter) FVB/N papillomas at 12-14 weeks after tumor initiation (9 from wildtype mice and 9 from Hras −/− mice). The overall mutation spectrum was highly similar to that in the tumors from the FVBBX population ( Fig. 1 and Supplementary Fig. 3) . Notably, these early papillomas had already acquired a similar proportion of G>T mutations to that observed in late papillomas from FVBBX mice, suggesting that most G>T mutations are acquired relatively early in the life of the tumor, during the phase of proliferation and chronic inflammation that is induced by the tumor-promoting TPA. Analysis of CNVs in early papillomas identified copy number gains of chromosome 7, which contains the mutant Hras gene, exclusively in papillomas from wild-type mice, as the only recurrent and significant early event (Supplementary Fig. 4) . The striking absence of additional copy number events in these early tumors suggests that the acquisition of CNVs seen in the original cohort is a later event that is associated with tumor progression.
DISCUSSION
We have exploited a classical skin tumor model in a genetically heterogeneous mouse population to investigate the evolutionary history of metastatic tumors using whole-exome sequencing of multiple lesions from the same animals. The ability to distinguish the parental alleles in each mouse shows that both Hras and Kras mutations are highly allele specific, thus demonstrating the important role of germline polymorphisms in determining mutation selection. Furthermore, the nature of the initiating event (Hras or Kras mutation) influences the subsequent genomic changes that take place, making this model useful for identifying potential drug candidates, such as Nuak2, that may be activated in tumors with Hras mutations. The use of specific initiating mutagens combined with clonal analysis has enabled us to distinguish early from late mutations. Whereas the initiating agent DMBA causes primarily A>T mutations across the genome, tumors accumulate G>T transversions during the early phase of TPA treatment, presumably owing to the induction of oxidative stress pathways that are linked to inflammation or to Ras signaling 34, 35 . The high frequency of point mutations in these skin tumors, which contrasts with the paucity of informative mutations in genetically engineered mouse (GEM) models 36, 37 , provides the opportunity to map, in great detail, the sequential mutations that take place during tumor evolution.
Our data support the 'parallel evolution' model, in which each metastasis is seeded directly by the primary tumor rather than via a lymph node 4, 21, 38 , as the major route to metastasis. Only one mouse (mouse 1949, Fig. 2f) showed evidence in favor of the 'linear' model ( Fig. 2 and Supplementary Fig. 2) . Notably, the number of shared mutations between primary and metastatic carcinomas in these mice was highly variable, suggesting that the seeding could occur either early or late in primary tumor evolution. Dissemination from the primary tumor can therefore occur very early and probably continuously 4 , but the capacity of disseminated tumor cells to grow out into full metastases is controlled by separate, presently unknown, factors (possibly secreted 'niche factors') 39, 40 that allow progressive growth at distant sites. However, the presence of multiple primary carcinomas in some animals, only one of which showed clear signs of metastasis, suggests that seeding is also controlled by tumor-intrinsic factors, which may include the repression or absence of neo-antigens that would stimulate recognition by the immune system 41 .
Our study design also allowed us to compare primary carcinomas that had metastasized with other carcinomas from the same animal that had not. The availability of these unique matched samples allowed us to perform gene expression analyses to identify a network of genes that were more highly expressed in metastasizing carcinomas than in their non-metastasizing counterparts, including Pdlim7 and Cd151, which have been previously linked to integrin signaling and tumor invasion 23, 24 . Further functional studies of these candidate genes in this model will be the subject of future investigations.
Another recent study of the evolution of metastasis in a mouse model of small-cell lung cancer, using next-generation sequencing, reached the conclusion that lymph nodes may be the gateway to distant metastases 37 , in agreement with the linear model. However, evidence for linear seeding was based mostly on a primary lung cancer and two metastases, one in the lymph node and one in the liver, from a single mouse. The reasons for the different conclusions from this study are unclear, but they may be due to the relative numbers of samples analyzed or to the use of a GEM model with very few nonsynonymous point mutations. During the revision stage of this manuscript, another study was published that used sequencing to identify relationships between primary skin tumors and their metastases 42 . In this study, the conclusions regarding tumor spread were, again, made on the basis of one informative mouse with two metastases. Thus, no clear conclusions can be drawn from these studies regarding the predominance of the linear versus parallel evolution models of metastasis.
The parallel evolution of metastases observed in this study is supported by a substantial body of clinical data showing that lymph node removal has no impact on patient survival [43] [44] [45] . The observation that primary and metastatic tumors in some mice share a very low number of mutations supports prior observations that early-stage tumors can disseminate even before reaching overt malignancy 4, 38 . Our data indicate that not only must these tumors have begun dissemination early but that they also acquired the ability to seed metastases, probably before the primary tumor advanced to a clinically recognizable carcinoma stage. Clearly, efforts to prevent dissemination or metastatic seeding in such cases would be futile, and other therapeutic approaches would be required. The availability of mouse models of cancer that mimic both the genomic heterogeneity and natural evolution of metastasis, such as that described here, will provide the opportunity to address these questions in more detail in a preclinical setting.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data are available under Gene Expression
Omnibus accession number GSE63967 and sequence data under European Nucleotide Archive study accession number ERP004081. 
ONLINE METHODS
Mouse backcross and carcinogenesis. Wild-type male SPRET/EiJ M. spretus mice were crossed to female Hras −/− FVB/N M. musculus mice to generate Hras-heterozygous F1s. Female F1s were crossed with male Hras −/− or Hrasheterozygous FVB/N M. musculus mice to generate FVBBX mice. Fifteen FVBBX mice were used in this experiment, 13 males and 2 females, chosen based on the availability of papilloma, primary carcinoma and metastasis samples for sequencing. Early papillomas were harvested from four female and three male FVB/N M. musculus mice, either wild type or Hras −/− , at 12-14 weeks after initiation with DMBA, at a size of 2-4 mm in diameter.
Mice were shaved and treated with 25 µg DMBA (Sigma-Aldrich) (dissolved in 200 µl acetone) at 8 weeks, and they subsequently received TPA (SigmaAldrich) (200 µL of a 10 −4 M solution in acetone) twice a week for 20 weeks, following an established chemical carcinogenesis protocol 5 . Carcinomas were surgically resected when they reached a size of >1 cm in longest diameter. Mice were sacrificed when disease progressed, as per animal care requirements. At sacrifice, papillomas and carcinomas were removed from skin, and all internal tumors were resected. Matched normal skin was also taken. A section of each primary carcinoma and metastasis was embedded in paraffin at the time of removal, for histological evaluation. The remaining tumor was flash frozen and stored at −80 °C, as was normal skin. No randomization or blinding was used in these experiments, as all mice underwent an identical treatment protocol. All animal experiments were approved by the University of California San Francisco (UCSF) Laboratory Animal Resource Center. Assessment of mouse tumor burden and size was carried out according to the UCSF Institutional Animal Care and Use Committee guidelines.
Histological classification. Formalin-fixed paraffin-embedded tumor was sectioned to 6 µm and H&E stained for histologic assessment.
Nucleic acid extraction. DNA was extracted from flash-frozen tumor and skin samples. Frozen tissue was ground and digested in 3 mg proteinase K (Bioline) overnight. DNA was separated by addition of phenol-chloroform and use of 5 PRIME Phase Lock Gel Heavy Tubes (Fisher Scientific), precipitated with isopropanol, washed with 70% ethanol and resuspended in nuclease-free water. Concentration and quality were determined by Nanodrop spectrophotometry and by PicoGreen (Invitrogen).
RNA was extracted from flash-frozen tumor and skin samples using TriZol reagent (Invitrogen) and cleaned with Qiagen RNeasy kit, according to the manufacturers' instructions. Concentration was determined by Nanodrop spectrophotometry, and RNA integrity number (RIN) was determined by an Agilent 2100 Bioanalyzer. All samples used for microarray analysis had a minimum RIN score of 6.5.
Exome sequencing, alignment and quality control. Exome enrichment and sequencing genomic libraries were prepared using the Illumina Paired-End Sample Prep Kit, following the manufacturer's instructions. Enrichment was performed as described previously 46 using the Agilent SureSelect Mouse All Exon kit according to the manufacturer's recommended protocol. Each exome was sequenced using a 76-bp paired-end protocol on the Illumina platform (GAII or HiSeq2000).
Tumor .bam files were aligned to the GRCm38/mm10 version of the M. musculus genome using BWA (version 0.5.10) (ref. 47) . After alignment, duplicates were marked and mate information was fixed using Picard (version 1.72; http://picard.sourceforge.net/). We then recalibrated base quality score and realigned reads around insertions and deletions (indels) using Genome Analysis Toolkit (GATK) (version 1.5-9) (ref. 48) . Finally, alignment and coverage metrics were collected using Picard. We sequenced an average of 66 million unique on-target reads per tumor. Targeted bases were sequenced to a mean depth of 50, and 78% of targeted bases were sequenced to 20× coverage or greater. There were no significant differences in depth of coverage or proportion of regions covered to 20× between tumor types.
Variant calling. SNVs were called using somatic variant detection program MuTect (version 1.1.4) (ref. 49) . Each tumor was called against its matched normal tissue, and calls were filtered against a database of known M. musculus FVB and M. spretus SPRET germline single-nucleotide polymorphisms (SNPs) available at ftp://ftp-mouse.sanger.ac.uk/ (release 1303, mgp.v3), as well as against a panel of normal skins from this experiment. MuTect was run with the 'required_maximum_alt_allele_mapping_quality_score' parameter set to 60, as the mixed genetic background of our FVBBX cross resulted in a number of poorly mapping reads we wished to exclude. Results were further filtered to calls with a minimum read depth of 10 and with a minimum mutant allele fraction of 10%. Variants were annotated using Annovar (downloaded on 2/13/2014) 50 , and these annotations were used as the basis for assessing exonic variants as synonymous, nonsynonymous, stop-gain or stop-loss. Mutations were compared to mutations observed in human cancers using the COSMIC database (version 68, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/download) 51 . Genes were selected for display (Fig. 4) based on whether they were commonly mutated in HNSCC or cutaneous skin SCC and on genes on a previous published list of cancer driver genes 52 .
Copy number calling was done with CNVkit 53 , and a tumor's copy number status was called against a panel of normal skins from this experiment. Raw copy number gain was adjusted to remove dilution from contaminating normal cells, with contamination determined by PyClone estimates (see below). Whole chromosome gains were considered to be those in which over 90% of the chromosome was gained and the weighted-mean amplification log 2 was greater than 0.4, implying trisomy in at least 30% of cells. Focal copy number events were determined as those for which the average copy number change for all exons of the gene had a log 2 increase of 0.6 or a log 2 decrease of −1 (corresponding to a 50% gain or loss of alleles).
Mutation validation.
To validate our mutation calls, we sequenced 205 SNVs to a median depth of 7,080 reads using MiSeq. We obtained an 86% validation rate.
PCR and sequencing. Primers for each candidate SNP were designed as nested pairs using Primer3 (refs. 54,55) . External amplicons were fixed at 400-800 bp, and internal amplicons were fixed at 250-300 bp. Internal primer pairs had partial Illumina adaptor sequences added to allow the construction of barcoded Illumina libraries. Tail sequences are: left adaptor 5′-ACACTCTTTCCCTACAC GACGCTCTTCCGATCT-3′, right adaptor 5′-TCGGCATTCCTGCTGAACC GCTCTTCCGATCT-3′. PCR was performed using hot start Taq DNA polymerase according to the manufacturer's instructions (Thermo Scientific). PCR1 (external primers) used a touchdown PCR approach for increased specificity. The products of PCR1 were diluted 100× and used as a template for PCR2, which added the partial Illumina adaptor tails. Candidate SNP PCRs for the same tumor were then pooled, and each tumor was barcoded with a different full-length Illumina adaptor barcode in a short PCR3 (15 cycles), so that each tumor could be decoded after sequencing. Resulting tumor-specific PCRs were pooled, cleaned up with 0.8× AmpureXP beads (Beckman Coulter), quantified and run on an Illumina MiSeq 150-bp PE run.
Data analysis.
Illumina adaptor sequence and low-quality bases (<20) were trimmed from reads using cutadapt 56 (https://cutadapt.readthedocs.org/en/ stable/). Reads were mapped to the GRCm38 build of the mouse genome using BWA mem 47 (http://bio-bwa.sourceforge.net/). Because amplicon sequencing was used, duplicate reads were not marked. Samtools mpileup and bcftools call 57 (http://www.htslib.org/) were used to output reference or alternate base calls and allele depths for the candidate positions. Samples were analyzed as groups of matched, normal skin and tumor samples. SNVs were considered validated if they contained at least 70 reads supporting the expected mutation. Clonality. Clonality analysis was performed with PyClone (version 0.12.7) (ref. 58) . For inputs to PyClone, reference and variant read depths were taken from the MuTect output, and copy number at each locus was determined from the CNVkit output. Clonal and subclonal mutation clusters were determined npg from the PyClone results table and compared with the PyClone cellular frequency plots for confirmation. Clonal mutations were those present in all tumor cells; subclonal mutations were those present in only a fraction of tumor cells.
Phylogenies.
To build phylogenetic trees, absolute distance matrices were calculated based on the presence of mutations in the sample, which were based on filtered MuTect calls. Rooted trees were built with the use of the 'analyses of phylogenetics and evolution' (APE) package and the Manhattan calculation method implemented in R version 2.15. Metastases were matched to primary tumors on the basis of shared mutations.
Identification of early and late mutations. Early and late mutations were identified with two methods. In the first method, mutations from 26 metastases with matched primaries were divided into those that were shared with the primary (early) and those that were not shared (later). Tumors used in this method included a representation of SCCs and spindle tumors and of Hras-driven and Kras-driven tumors. In the second method, mutations in 12 tumors, in which multiple clones were identified with PyClone, were divided into fully clonal mutations (i.e., those present in all tumor cells) (early) and subclonal mutations (i.e., those present in only a fraction of tumor cells) (late). Tumors used in this method included a representation of papillomas, SCCs and spindle tumors; Hras-driven and Kras-driven tumors; and primary tumors and metastases.
Evaluation of candidate 'metastasis genes' . To assess whether we had any candidate 'metastasis genes' that could explain why certain primary tumors metastasized whereas others did not, we first examined genes that were recurrently mutated in metastasizing carcinomas. We found 22 genes that were mutated more than once in a metastasizing carcinoma; however, 19 of these were also mutated in non-metastasizing carcinomas at a similar frequency. The remaining three genes-Foxn4, Scn9a and Sspo-were found mutated in one or more papillomas and thus also did not present good candidates. We found that Pdlim7, Tecpr2 and Cd151 were expressed at higher levels in metastasizing carcinomas, although, of these, expression of Pdlim7 was significant after a multiple-test correction (P = 6.4 × 10 −6 ). None of these genes carried any mutations in any primary or metastatic carcinomas. No genes were expressed at significantly lower levels in metastasizing carcinomas.
Allele specificity analysis. To determine the allele specificity of Hras and Kras mutations, 75-bp reads that contained both the mutation and nearby SNPs were extracted from the .bam file using mpileup 56 , and the genotype of mutated allele was determined. For codon 61 mutations in Hras, the SNPs used to determine genotype were chr7:141192537, A (FVB) or G (SPRET) and chr7:141192567, G (FVB) or A (SPRET). For codon 61 mutations in Kras, the SNPs used were chr6:145234318, T (FVB) or C (SPRET) and chr6:145234388 G (FVB) or A (SPRET). For mutations in Kras codons 12 and 13, the SNPs used were chr6:145246755, G (FVB) or A (SPRET) and chr6:145246782 C (FVB) or T (SPRET). Significance was evaluated using a chi-squared test.
Expression microarrays, normalization and differential expression. Gene expression was quantified using Affymetrix MoGene ST 1.1 arrays hybridized on an Affymetrix GeneTitan instrument. Affymetrix MoGene arrays were normalized using the oligo package 59 , and a probe database was prepared for FVBBX mice to avoid probes which intersect known FVB/N or SPRET/EiJ SNPs (http://davidquigley.com/equalizer.html) 60 . Differential expression for genes on chromosome 1 and for comparison of metastasizing versus nonmetastasizing carcinomas was done using the siggenes package in R, with a false discovery rate threshold of 0.01. Microarray data is available under GEO accession number GSE63967 and sequence data under ENA study accession number ERP004081.
